Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF20513 extension study in mild Alzheimer's disease
NCT02388152Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- Mar 2015
- Primary completion
- Jul 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 1, open-label trial of Lu AF20513 in Alzheimer's disease (AD) (4 arms), sponsored by Lundbeck. Primary endpoints: Safety and tolerability assessed by composite outcome measure and Antibody titre. Started Mar 2015; status: terminated.
02
Drugs
Lu AF20513
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02388152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388152.